Who is sponsoring BUS-PD?

BUS-PD is sponsored by Oregon Health and Science University.

What condition does BUS-PD study?

BUS-PD studies Parkinson's Disease, Dyskinesias, Movement Disorders.

What drugs are being tested in BUS-PD?

Interventions: Buspirone, Placebo.

What is the status of BUS-PD?

BUS-PD is currently TERMINATED.

Last reviewed 2021-03-03 · How we verify

Buspirone, in Combination With Amantadine, for the Treatment of Levodopa-induced Dyskinesia (BUS-PD)

NCT02589340 Phase 1 TERMINATED

The primary objective of this study is to evaluate the efficacy of buspirone in combination with amantadine in reducing levodopa-induced dyskinesia (LID) in patients with Parkinson's disease (PD).

Details

Lead sponsor	Oregon Health and Science University
Phase	Phase 1
Status	TERMINATED
Enrolment	6
Start date	2016-01
Completion	2021-02-23

Conditions

Parkinson's Disease
Dyskinesias
Movement Disorders

Interventions

Buspirone
Placebo

Primary outcomes

Area Under the Curve - Dyskinesia - Forceplate — 6 hour levodopa dose cycle
forceplate measurements of levodopa induced dyskinesia taken every 1/2 hour for 6 hours.
Dyskinesia - UDysRS — up to 6 weeks
UDysRS total score comparison
Adverse Events — up to 6 weeks
Adverse Events Monitoring/Frequency

Countries

United States